TWP
NVS icon

Triad Wealth Partners’s Novartis NVS Stock Holding History

Triad Wealth Partners’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$300K Buy
1,949
+160
+9% +$24K 0.02% 446
2026
Q1 		$273K Buy
+1,789
New +$274K 0.02% 411
2024
Q3 		– Sell
-1,014
Closed -$108K – 615
2024
Q2 		$108K Buy
+1,014
New +$102K 0.06% 147

Other funds holding NVS

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Triad Wealth Partners's NVS Position: Q2 2026 in Review

Triad Wealth Partners increased its Novartis (NVS) stake by 8.9% in Q2 2026, buying an estimated $24K and bringing the position to 1,949 shares worth $300K. The position accounts for 0.02% of the portfolio, ranked #446.

Triad Wealth Partners first reported a position in NVS in Q2 2024 and has held it in 3 quarters since. 1,620 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Triad Wealth Partners held 1,949 shares of Novartis worth $300K as of Q2 2026.
  • Triad Wealth Partners bought 160 Novartis shares in Q2 2026, an estimated $24K.
  • Novartis made up 0.02% of Triad Wealth Partners's portfolio in Q2 2026, its #446 holding.
  • Triad Wealth Partners first reported a position in Novartis in Q2 2024 and has held it in 3 quarters since.
  • 1,620 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Triad Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.